Henry Schein, Inc. (HSIC) vs 10x Genomics, Inc. (TXG)
A side-by-side comparison of Henry Schein, Inc. and 10x Genomics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
HSIC
Henry Schein, Inc.
$84.84HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
TXG
10x Genomics, Inc.
$80.66HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
Total return — HSIC vs TXG
growth of $100 · dividends reinvested · last 7yHSIC +36.8% (+4.6%/yr)TXG +85.3% (+9.2%/yr)TXG compounded faster over this window
HSIC TXG
HSIC vs TXG: by the numbers
- •TXG is the larger company ($10.24B vs $9.66B market cap).
- •HSIC is profitable (2.96% net margin) while TXG runs a net loss (-12.18%).
- •TXG grew revenue faster over the past five years (8.74% vs 2.71% CAGR).
Metrics side by side
Valuation
| Metric | HSIC | TXG |
|---|---|---|
| P/E ratio | 24.73 | N/A |
| Forward P/E | 15.75 | N/A |
| PEG ratio | 7.83 | N/A |
| P/S ratio | 0.71 | 16.60 |
| P/B ratio | 3.06 | 12.40 |
| EV / EBITDA | 12.25 | N/A |
| FCF yield | 5.58% | 1.19% |
Profitability
| Metric | HSIC | TXG |
|---|---|---|
| Gross margin | 30.31% | 70.03% |
| Operating margin | 5.69% | -14.33% |
| Net margin | 2.96% | -12.18% |
| ROE | 12.77% | -9.10% |
| ROIC | 6.53% | -9.57% |
Growth (annualized)
| Metric | HSIC | TXG |
|---|---|---|
| Revenue CAGR (5Y) | 2.71% | 8.74% |
| EPS CAGR (5Y) | 3.14% | N/A |
| FCF CAGR (5Y) | 0.82% | N/A |
| Total return CAGR (5Y) | 1.39% | -7.24% |
Frequently asked
- Which has grown faster, HSIC or TXG?
- Over the past five years, TXG grew revenue faster — HSIC at a 2.71% CAGR versus TXG at 8.74%.
- Is HSIC or TXG more profitable?
- HSIC runs the higher net margin — HSIC at 2.96% versus TXG at -12.18%.
- How have HSIC and TXG total returns compared?
- Over the past 5 years, HSIC delivered 1.39% and TXG delivered -7.24% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Henry Schein P/E ratioHenry Schein ROE10x Genomics ROEHenry Schein operating margin10x Genomics operating marginHenry Schein revenue growth10x Genomics revenue growthHenry Schein free cash flow10x Genomics free cash flow
Henry Schein & 10x Genomics appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.